Astera Labs, Inc. (NASDAQ:ALAB) Stock Position Lowered by Linden Thomas Advisory Services LLC

Linden Thomas Advisory Services LLC decreased its position in Astera Labs, Inc. (NASDAQ:ALAB) by 0.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 52,161 shares of the company’s stock after selling 313 shares during the period. Astera Labs accounts for about 0.9% of Linden Thomas Advisory Services LLC’s investment portfolio, making the stock its 6th biggest position. Linden Thomas Advisory Services LLC’s holdings in Astera Labs were worth $6,909,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of ALAB. Geneos Wealth Management Inc. bought a new stake in shares of Astera Labs in the 4th quarter valued at about $36,000. ORG Wealth Partners LLC purchased a new position in Astera Labs during the fourth quarter valued at approximately $42,000. Hollencrest Capital Management bought a new position in Astera Labs in the third quarter worth approximately $26,000. GAMMA Investing LLC lifted its holdings in Astera Labs by 78.3% during the fourth quarter. GAMMA Investing LLC now owns 510 shares of the company’s stock worth $68,000 after buying an additional 224 shares during the period. Finally, Berbice Capital Management LLC bought a new stake in Astera Labs during the 4th quarter valued at $86,000. Institutional investors own 60.47% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Michael Truett Tate sold 16,000 shares of the company’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $117.84, for a total value of $1,885,440.00. Following the sale, the chief financial officer now owns 1,412,888 shares in the company, valued at $166,494,721.92. This represents a 1.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Manuel Alba sold 11,000 shares of Astera Labs stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $117.50, for a total value of $1,292,500.00. Following the transaction, the director now owns 456,863 shares of the company’s stock, valued at approximately $53,681,402.50. This represents a 2.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,690,452 shares of company stock valued at $167,581,256.

Astera Labs Stock Performance

Shares of ALAB stock opened at $115.55 on Friday. The business has a fifty day moving average of $123.01 and a 200 day moving average of $78.77. Astera Labs, Inc. has a 1 year low of $36.22 and a 1 year high of $147.39.

Astera Labs (NASDAQ:ALAB) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.06. Astera Labs had a negative return on equity of 15.57% and a negative net margin of 30.69%. The firm had revenue of $113.10 million during the quarter, compared to analysts’ expectations of $97.50 million. Astera Labs’s revenue was up 47.1% on a year-over-year basis. Equities research analysts anticipate that Astera Labs, Inc. will post -0.45 EPS for the current year.

Analysts Set New Price Targets

ALAB has been the subject of several recent research reports. Roth Mkm boosted their price target on Astera Labs from $80.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Barclays boosted their target price on shares of Astera Labs from $87.00 to $135.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Northland Capmk cut shares of Astera Labs from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 2nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $65.00 price objective on shares of Astera Labs in a research report on Wednesday, October 9th. Finally, Northland Securities cut shares of Astera Labs from an “outperform” rating to a “market perform” rating and increased their target price for the company from $100.00 to $120.00 in a research report on Thursday, January 2nd. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $109.75.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.